Data from Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median DOR of ~4 Years in Patients Achieving CR with JELMYTO Published in The Journal of Urology
“Prior research has emphasized that the main treatment objectives for LG-UTUC should focus on preventing relapse and preserving organ function, given the low likelihood of disease progression,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “We are pleased with the study’s results, which offer strong evidence supporting the long-term effectiveness of JELMYTO as a primary treatment for LG-UTUC, with increasing data showing extended response duration.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.